J9329 HCPCS Level II code: Injection, tislelizumab-jsgr, 1mg
J9329 is the HCPCS code for “Injection, tislelizumab-jsgr, 1mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J9329Injection, tislelizumab-jsgr, 1mg
Short description: Inj, tislelizumab-jsgr
HCPCS · United States
Medicare details
The indicators CMS publishes with J9329 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Chemotherapy
- Added
- Oct 1, 2024
Where J9329 sits
- 1J codesDrugs administered other than orally
- 2Active code J9329Injection, tislelizumab-jsgr, 1mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J9329 mean?
J9329 is the HCPCS code for “Injection, tislelizumab-jsgr, 1mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J9329?
CMS lists J9329’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J9329
All J codesJ9322Injection, pemetrexed (bluepoint), not therapeutically equivalent to j9305, 10 mgJ9323Injection, pemetrexed ditromethamine, 10 mgJ9324Injection, pemetrexed (pemrydi rtu), 10 mgJ9325Injection, talimogene laherparepvec, per 1 million plaque forming unitsJ9326Injection, telisotuzumab vedotin-tllv, 1 mgJ9328Injection, temozolomide, 1 mgJ9330Injection, temsirolimus, 1 mgJ9331Injection, sirolimus protein-bound particles, 1 mgJ9332Injection, efgartigimod alfa-fcab, 2mgJ9333Injection, rozanolixizumab-noli, 1 mgJ9334Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfcJ9340Injection, thiotepa, 15 mg